Drug intelligence / Profile preview

maraviroc + darunavir + ritonavir

Development stage: Discontinued
Lead developer: ViiV Healthcare
Modality: Small Molecules
Administration: Oral

Overview

A combination antiretroviral therapy for HIV-1 infection consisting of maraviroc (a CCR5 antagonist), darunavir (a protease inhibitor), and ritonavir (a pharmacokinetic enhancer). This combination works by blocking HIV entry into cells and inhibiting viral replication. Pharmacokinetic studies show significant interactions, with darunavir/ritonavir increasing maraviroc exposure approximately 4-fold, requiring dose adjustment of maraviroc to 150 mg twice daily when used with darunavir/ritonavir.

Brand names: SelzentryPrezistaNorvir
Other names: Humulin R U-100-Northwestern University-HIV-1 infection

Targets

CYP3A4 (Cytochrome P450 3A4)CCR5 (C-C chemokine receptor type 5)PR (Progesterone receptor)

Beyond the preview

Go deeper on maraviroc + darunavir + ritonavir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on maraviroc + darunavir + ritonavir.

Explore the full profile